JP4115518B2 - 新規３，５−ジオキソ−（２ｈ，４ｈ）−１，２，４−トリアジン誘導体、それらの調製および薬剤としての使用 - Google Patents
新規３，５−ジオキソ−（２ｈ，４ｈ）−１，２，４−トリアジン誘導体、それらの調製および薬剤としての使用 Download PDFInfo
- Publication number
- JP4115518B2 JP4115518B2 JP51834596A JP51834596A JP4115518B2 JP 4115518 B2 JP4115518 B2 JP 4115518B2 JP 51834596 A JP51834596 A JP 51834596A JP 51834596 A JP51834596 A JP 51834596A JP 4115518 B2 JP4115518 B2 JP 4115518B2
- Authority
- JP
- Japan
- Prior art keywords
- dioxo
- triazine
- piperazino
- methyl
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical class O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 3
- 239000003814 drug Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 36
- -1 benzodioxanyl-methylamino Chemical group 0.000 claims abstract description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- OLNKJRYQWXCNJZ-UHFFFAOYSA-N 2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(N2CCN(CCCCN3C(NC(=O)C=N3)=O)CC2)=C1 OLNKJRYQWXCNJZ-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- SIHVBMSILTULMC-UHFFFAOYSA-N 2-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 SIHVBMSILTULMC-UHFFFAOYSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- IRTCWPNSLGQHOR-WLHGVMLRSA-N (e)-but-2-enedioic acid;4-methyl-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2,4-triazine-3,5-dione Chemical compound OC(=O)\C=C\C(O)=O.O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 IRTCWPNSLGQHOR-WLHGVMLRSA-N 0.000 claims description 2
- HKFWMRVVPZKYDL-UHFFFAOYSA-N 2-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1,2,4-triazine-3,5-dione;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC(=O)C=N3)=O)CC2)=C1 HKFWMRVVPZKYDL-UHFFFAOYSA-N 0.000 claims description 2
- ABFHOGGLXMLEPV-UHFFFAOYSA-N 2-[3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propyl]-1,2,4-triazine-3,5-dione Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCCN3C(NC(=O)C=N3)=O)CC2)=C1 ABFHOGGLXMLEPV-UHFFFAOYSA-N 0.000 claims description 2
- XVSZHHFWQXGSAS-UHFFFAOYSA-N 2-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 XVSZHHFWQXGSAS-UHFFFAOYSA-N 0.000 claims description 2
- SRBUSSMRAKNUBQ-UHFFFAOYSA-N 2-[4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2C=C(Cl)C(Cl)=CC=2)CC1 SRBUSSMRAKNUBQ-UHFFFAOYSA-N 0.000 claims description 2
- HHTMBTZPFSSIOB-UHFFFAOYSA-N 4-methyl-2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 HHTMBTZPFSSIOB-UHFFFAOYSA-N 0.000 claims description 2
- ZMJJMPICDRNVFX-UHFFFAOYSA-N 4-methyl-2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione;hydrochloride Chemical compound Cl.O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 ZMJJMPICDRNVFX-UHFFFAOYSA-N 0.000 claims description 2
- LBWJXWHODINEDT-UHFFFAOYSA-N 6-methyl-2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione Chemical compound O=C1NC(=O)C(C)=NN1CCCCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 LBWJXWHODINEDT-UHFFFAOYSA-N 0.000 claims description 2
- OKBREPQLGPVQKF-UHFFFAOYSA-N 6-phenyl-2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(N2CCN(CCCCN3C(NC(=O)C(C=4C=CC=CC=4)=N3)=O)CC2)=C1 OKBREPQLGPVQKF-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229910052799 carbon Chemical group 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 235000012631 food intake Nutrition 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- CRCNFIAOWOVHSD-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[4-[2,3-dihydro-1,4-benzodioxin-3-ylmethyl(methyl)amino]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound OC(=O)\C=C\C(O)=O.C1OC2=CC=CC=C2OC1CN(C)CCCCN1N=CC(=O)N(C)C1=O CRCNFIAOWOVHSD-WLHGVMLRSA-N 0.000 claims 1
- VGYSKJUYWGFWTE-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[4-[4-(3-methoxypyridin-2-yl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound OC(=O)\C=C\C(O)=O.COC1=CC=CN=C1N1CCN(CCCCN2C(N(C)C(=O)C=N2)=O)CC1 VGYSKJUYWGFWTE-WLHGVMLRSA-N 0.000 claims 1
- HDVPJLSZCGLLPM-UHFFFAOYSA-N 2-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]-4-methyl-1,2,4-triazine-3,5-dione;hydrochloride Chemical compound Cl.O=C1N(C)C(=O)C=NN1CCCNCC1OC2=CC=CC=C2OC1 HDVPJLSZCGLLPM-UHFFFAOYSA-N 0.000 claims 1
- LJBCRWZSSFRHJK-UHFFFAOYSA-N 2-[4-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCNCC1OC2=CC=CC=C2OC1 LJBCRWZSSFRHJK-UHFFFAOYSA-N 0.000 claims 1
- LOTOEDHKWFOSAJ-UHFFFAOYSA-N 2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2,4-triazine-3,5-dione Chemical compound O=C1NC(=O)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 LOTOEDHKWFOSAJ-UHFFFAOYSA-N 0.000 claims 1
- MEKSQRMXWZHFIP-UHFFFAOYSA-N 2-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound COC1=CC=CC=C1N1CCN(CCCCN2C(N(C)C(=O)C=N2)=O)CC1 MEKSQRMXWZHFIP-UHFFFAOYSA-N 0.000 claims 1
- KTQHITPMEPWHBZ-UHFFFAOYSA-N 2-[4-[4-(3,5-dichlorophenyl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2C=C(Cl)C=C(Cl)C=2)CC1 KTQHITPMEPWHBZ-UHFFFAOYSA-N 0.000 claims 1
- PRQDJWKIHCOQNU-UHFFFAOYSA-N 2-[4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound CC1=CC(C)=NC(N2CCN(CCCCN3C(N(C)C(=O)C=N3)=O)CC2)=N1 PRQDJWKIHCOQNU-UHFFFAOYSA-N 0.000 claims 1
- VOOIEBXOOGMVSU-UHFFFAOYSA-N 2-[4-[4-(4-chloropyrimidin-2-yl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2N=C(Cl)C=CN=2)CC1 VOOIEBXOOGMVSU-UHFFFAOYSA-N 0.000 claims 1
- YXCUQEZPBILLCZ-UHFFFAOYSA-N 2-[4-[4-(4-methoxypyrimidin-2-yl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound COC1=CC=NC(N2CCN(CCCCN3C(N(C)C(=O)C=N3)=O)CC2)=N1 YXCUQEZPBILLCZ-UHFFFAOYSA-N 0.000 claims 1
- NTSHPAPLJYCWAP-UHFFFAOYSA-N 4,6-dimethyl-2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C(C)=NN1CCCCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 NTSHPAPLJYCWAP-UHFFFAOYSA-N 0.000 claims 1
- CBVUZKZTENNBKS-UHFFFAOYSA-N 4-methyl-2-[4-[4-(4-methylpyrimidin-2-yl)piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione Chemical compound CC1=CC=NC(N2CCN(CCCCN3C(N(C)C(=O)C=N3)=O)CC2)=N1 CBVUZKZTENNBKS-UHFFFAOYSA-N 0.000 claims 1
- XJNKAXHWXIOLPZ-UHFFFAOYSA-N 4-methyl-2-[4-[4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2N=C(C=CN=2)C(F)(F)F)CC1 XJNKAXHWXIOLPZ-UHFFFAOYSA-N 0.000 claims 1
- OFWIUIOSRCJWRJ-UHFFFAOYSA-N 4-methyl-6-phenyl-2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)C(C=2C=CC=CC=2)=NN1CCCCN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 OFWIUIOSRCJWRJ-UHFFFAOYSA-N 0.000 claims 1
- NMYAHEULKSYAPP-UHFFFAOYSA-N Eptapirone Chemical compound O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 NMYAHEULKSYAPP-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- 239000000741 silica gel Substances 0.000 description 36
- 229910002027 silica gel Inorganic materials 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000001530 fumaric acid Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960002495 buspirone Drugs 0.000 description 3
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000000862 serotonergic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 2
- JHNURUNMNRSGRO-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanamine Chemical compound C1=CC=C2OC(CN)COC2=C1 JHNURUNMNRSGRO-UHFFFAOYSA-N 0.000 description 2
- IGMWDVGQYKDUEB-UHFFFAOYSA-N 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-2-ylmethanamine Chemical compound C1=CC=C2OC(CN)COC2=N1 IGMWDVGQYKDUEB-UHFFFAOYSA-N 0.000 description 2
- CJDGWFJLTXOBNE-UHFFFAOYSA-N 2-[4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]butyl]-1,2,4-triazine-3,5-dione Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCCCN3C(NC(=O)C=N3)=O)CC2)=C1 CJDGWFJLTXOBNE-UHFFFAOYSA-N 0.000 description 2
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YLVUOUFVSATDJL-UHFFFAOYSA-N CC1=NC(=NC(=C1)C)N1CCN(CC1)CCCCN1N=CC(NC1=O)=O Chemical compound CC1=NC(=NC(=C1)C)N1CCN(CC1)CCCCN1N=CC(NC1=O)=O YLVUOUFVSATDJL-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000010454 slate Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- PWAIYQXMMHKHJY-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]-4-methyl-1,2,4-triazine-3,5-dione Chemical compound OC(=O)\C=C\C(O)=O.O=C1N(C)C(=O)C=NN1CCCNCC1OC2=CC=CC=C2OC1 PWAIYQXMMHKHJY-WLHGVMLRSA-N 0.000 description 1
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- PXFJLKKZSWWVRX-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)piperazine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCNCC1 PXFJLKKZSWWVRX-UHFFFAOYSA-N 0.000 description 1
- LISGMSBYRAXPJH-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)piperazine Chemical compound ClC1=CC(Cl)=CC(N2CCNCC2)=C1 LISGMSBYRAXPJH-UHFFFAOYSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
- KLNMSBVPRVBART-UHFFFAOYSA-N 1-(3-methoxypyridin-2-yl)piperazine Chemical compound COC1=CC=CN=C1N1CCNCC1 KLNMSBVPRVBART-UHFFFAOYSA-N 0.000 description 1
- XDYRIGIBUWJCMR-UHFFFAOYSA-N 1-(7-methoxynaphthalen-1-yl)piperazine Chemical compound C12=CC(OC)=CC=C2C=CC=C1N1CCNCC1 XDYRIGIBUWJCMR-UHFFFAOYSA-N 0.000 description 1
- KRIFIXRWMBYQLK-UHFFFAOYSA-N 1-bromo-4-methylsulfanyl-1,2,4-triazinan-5-one Chemical compound CSN1CNN(Br)CC1=O KRIFIXRWMBYQLK-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 1
- SVALBOPDZQEZBO-UHFFFAOYSA-N 2-(4-chlorobutyl)-1,2,4-triazine-3,5-dione Chemical compound ClCCCCN1N=CC(=O)NC1=O SVALBOPDZQEZBO-UHFFFAOYSA-N 0.000 description 1
- SSBDEUDVXQSCLE-UHFFFAOYSA-N 2-(4-chlorobutyl)-3-methylsulfanyl-1,2,4-triazin-5-one Chemical compound CSC1=NC(=O)C=NN1CCCCCl SSBDEUDVXQSCLE-UHFFFAOYSA-N 0.000 description 1
- ZVQJGCWRNIVFKV-UHFFFAOYSA-N 2-(4-chlorobutyl)-4-methyl-1,2,4-triazine-3,5-dione Chemical compound CN1C(=O)C=NN(CCCCCl)C1=O ZVQJGCWRNIVFKV-UHFFFAOYSA-N 0.000 description 1
- BZJOQWGOILBGJR-UHFFFAOYSA-N 2-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-4-methyl-1,2,4-triazine-3,5-dione;hydrochloride Chemical compound Cl.O=C1N(C)C(=O)C=NN1CCCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 BZJOQWGOILBGJR-UHFFFAOYSA-N 0.000 description 1
- LWEWFRNMHQVGBM-UHFFFAOYSA-N 2-butyl-1,2,4-triazine-3,5-dione Chemical compound CCCCN1N=CC(=O)NC1=O LWEWFRNMHQVGBM-UHFFFAOYSA-N 0.000 description 1
- WBJVPAABGFBMJQ-UHFFFAOYSA-N 2-piperazin-1-yl-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(N2CCNCC2)=N1 WBJVPAABGFBMJQ-UHFFFAOYSA-N 0.000 description 1
- ZJFYWFHUHCUNTH-UHFFFAOYSA-N 3-methylsulfanyl-2h-1,2,4-triazin-5-one Chemical compound CSC1=NC(=O)C=NN1 ZJFYWFHUHCUNTH-UHFFFAOYSA-N 0.000 description 1
- XHHHXWUBPUAMPZ-UHFFFAOYSA-N 3-methylsulfanyl-6-phenyl-2h-1,2,4-triazin-5-one Chemical compound N1C(SC)=NC(=O)C(C=2C=CC=CC=2)=N1 XHHHXWUBPUAMPZ-UHFFFAOYSA-N 0.000 description 1
- QLTXFTSBONWMPM-UHFFFAOYSA-N 4,6-dimethyl-2-piperazin-1-ylpyrimidine Chemical compound CC1=CC(C)=NC(N2CCNCC2)=N1 QLTXFTSBONWMPM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MQSYDNGEAVHZAN-UHFFFAOYSA-N 4-chloro-2-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=NC(N2CCNCC2)=N1 MQSYDNGEAVHZAN-UHFFFAOYSA-N 0.000 description 1
- UWNRWWIRIZDKLH-UHFFFAOYSA-N 4-methoxy-2-piperazin-1-ylpyrimidine Chemical compound COC1=CC=NC(N2CCNCC2)=N1 UWNRWWIRIZDKLH-UHFFFAOYSA-N 0.000 description 1
- QMFLDCBHGGRGNY-UHFFFAOYSA-N 4-methyl-2-piperazin-1-ylpyrimidine Chemical compound CC1=CC=NC(N2CCNCC2)=N1 QMFLDCBHGGRGNY-UHFFFAOYSA-N 0.000 description 1
- XEMKAWDHPYXCKU-UHFFFAOYSA-N 4-methyl-2h-1,2,4-triazine-3,5-dione Chemical compound CN1C(=O)C=NNC1=O XEMKAWDHPYXCKU-UHFFFAOYSA-N 0.000 description 1
- GFJDLRANNRSMCK-UHFFFAOYSA-N 6-amino-2h-1,2,4-triazine-3,5-dione Chemical class NC1=NNC(=O)NC1=O GFJDLRANNRSMCK-UHFFFAOYSA-N 0.000 description 1
- JPQKKTUTCVOYJW-UHFFFAOYSA-N 6-methyl-3-methylsulfanyl-3,4-dihydro-2h-1,2,4-triazin-5-one Chemical compound CSC1NN=C(C)C(=O)N1 JPQKKTUTCVOYJW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- RJIJIPUHQPCXHM-UHFFFAOYSA-N CC1=NNC(SC)=NC1=O Chemical compound CC1=NNC(SC)=NC1=O RJIJIPUHQPCXHM-UHFFFAOYSA-N 0.000 description 1
- 0 CSC1=NC(C=O)C(CC*)=NN1 Chemical compound CSC1=NC(C=O)C(CC*)=NN1 0.000 description 1
- YQQOCRLMAWHARF-UHFFFAOYSA-N ClC1=CC=NC(N2CCN(CCCCN3C(NC(=O)C=N3)=O)CC2)=N1 Chemical compound ClC1=CC=NC(N2CCN(CCCCN3C(NC(=O)C=N3)=O)CC2)=N1 YQQOCRLMAWHARF-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FUDVJHLPEJTZLO-UHFFFAOYSA-N N#CN(C(C=NN1CCCCN(CC2)CCN2c2cccc(Cl)c2)=O)C1=O Chemical compound N#CN(C(C=NN1CCCCN(CC2)CCN2c2cccc(Cl)c2)=O)C1=O FUDVJHLPEJTZLO-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR94/14544 | 1994-12-02 | ||
| FR9414544A FR2727682A1 (fr) | 1994-12-02 | 1994-12-02 | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
| PCT/FR1995/001589 WO1996016949A1 (fr) | 1994-12-02 | 1995-12-01 | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10510286A JPH10510286A (ja) | 1998-10-06 |
| JP4115518B2 true JP4115518B2 (ja) | 2008-07-09 |
Family
ID=9469440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51834596A Expired - Fee Related JP4115518B2 (ja) | 1994-12-02 | 1995-12-01 | 新規３，５−ジオキソ−（２ｈ，４ｈ）−１，２，４−トリアジン誘導体、それらの調製および薬剤としての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5977106A (OSRAM) |
| EP (1) | EP0794949B1 (OSRAM) |
| JP (1) | JP4115518B2 (OSRAM) |
| AT (1) | ATE169008T1 (OSRAM) |
| AU (1) | AU705900B2 (OSRAM) |
| CA (1) | CA2206794C (OSRAM) |
| DE (1) | DE69503803T2 (OSRAM) |
| DK (1) | DK0794949T3 (OSRAM) |
| ES (1) | ES2121441T3 (OSRAM) |
| FR (1) | FR2727682A1 (OSRAM) |
| NZ (1) | NZ297822A (OSRAM) |
| WO (1) | WO1996016949A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859014A (en) * | 1995-06-09 | 1999-01-12 | Syntex (U.S.A.) Inc. | Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists |
| ATE201016T1 (de) * | 1995-06-09 | 2001-05-15 | Hoffmann La Roche | Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten |
| EP0875512A3 (en) * | 1997-04-16 | 1999-04-07 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) | New naphthylpiperazine derivatives with antipsychotic activity |
| FR2769913B1 (fr) * | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine |
| FR2769912B1 (fr) * | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| AU4566399A (en) * | 1998-06-15 | 2000-01-05 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
| US6376494B1 (en) | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
| US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| US6656950B2 (en) * | 2001-04-25 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| AU2005235422B2 (en) * | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| CA2576812A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
| US8168786B2 (en) * | 2004-12-28 | 2012-05-01 | The Trustees Of Columbia University In The City Of New York | Radiolabeled compounds and uses thereof |
| WO2006083424A2 (en) * | 2004-12-28 | 2006-08-10 | The Trustees Of Columbia University In The City Of New York | Radiolabeled compounds and uses thereof |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| JP2008538741A (ja) * | 2005-03-04 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鬱病の治療用及び／又は予防用の医薬組成物 |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| CA2608249A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| CA2608363A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| EP1888070A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of sexual dysfunctions due to medical conditions |
| ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
| WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| JP2009536176A (ja) * | 2006-05-09 | 2009-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 閉経後の性的欲求障害の治療のためのフリバンセリンの使用 |
| EP2037927B1 (en) * | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| WO2008019996A2 (en) | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
| JP5220746B2 (ja) | 2006-08-25 | 2013-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 制御放出システム及びその製造方法 |
| PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
| CN101870696B (zh) * | 2009-04-22 | 2012-08-29 | 连云港恒邦医药科技有限公司 | 具有多巴胺D2和5-HT2a双重活性的N-芳基哌嗪衍生物 |
| WO2011140360A1 (en) | 2010-05-05 | 2011-11-10 | The Trustees Of Columbia University In The City Of New York | Radiolabeled compounds and uses thereof |
| CN108440505A (zh) * | 2018-03-30 | 2018-08-24 | 中南大学 | 依他匹隆的全合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5036070A (en) * | 1990-06-13 | 1991-07-30 | American Home Products Corporation | Polycyclic phenalkyl amines as psychotropic agents |
| MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
| FR2680172B1 (fr) * | 1991-08-05 | 1993-11-19 | Fabre Medicament Pierre | Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique. |
| CA2090767A1 (en) * | 1992-03-06 | 1993-09-07 | Gerald Guillaumet | 1,4-dioxino[2,3-b]pyridine derivatives |
| FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
-
1994
- 1994-12-02 FR FR9414544A patent/FR2727682A1/fr active Granted
-
1995
- 1995-12-01 NZ NZ297822A patent/NZ297822A/en not_active IP Right Cessation
- 1995-12-01 WO PCT/FR1995/001589 patent/WO1996016949A1/fr not_active Ceased
- 1995-12-01 CA CA002206794A patent/CA2206794C/fr not_active Expired - Fee Related
- 1995-12-01 DE DE69503803T patent/DE69503803T2/de not_active Expired - Lifetime
- 1995-12-01 AT AT95941754T patent/ATE169008T1/de active
- 1995-12-01 US US08/849,655 patent/US5977106A/en not_active Expired - Lifetime
- 1995-12-01 EP EP95941754A patent/EP0794949B1/fr not_active Expired - Lifetime
- 1995-12-01 ES ES95941754T patent/ES2121441T3/es not_active Expired - Lifetime
- 1995-12-01 DK DK95941754T patent/DK0794949T3/da active
- 1995-12-01 AU AU43067/96A patent/AU705900B2/en not_active Ceased
- 1995-12-01 JP JP51834596A patent/JP4115518B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU705900B2 (en) | 1999-06-03 |
| EP0794949A1 (fr) | 1997-09-17 |
| CA2206794C (fr) | 2009-11-17 |
| NZ297822A (en) | 1998-09-24 |
| DK0794949T3 (da) | 1999-05-03 |
| ES2121441T3 (es) | 1998-11-16 |
| DE69503803D1 (de) | 1998-09-03 |
| FR2727682A1 (fr) | 1996-06-07 |
| EP0794949B1 (fr) | 1998-07-29 |
| DE69503803T2 (de) | 1999-04-15 |
| US5977106A (en) | 1999-11-02 |
| ATE169008T1 (de) | 1998-08-15 |
| JPH10510286A (ja) | 1998-10-06 |
| WO1996016949A1 (fr) | 1996-06-06 |
| CA2206794A1 (fr) | 1996-06-06 |
| AU4306796A (en) | 1996-06-19 |
| FR2727682B1 (OSRAM) | 1997-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4115518B2 (ja) | 新規３，５−ジオキソ−（２ｈ，４ｈ）−１，２，４−トリアジン誘導体、それらの調製および薬剤としての使用 | |
| US5591743A (en) | 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT1A ligands | |
| JPH0314563A (ja) | 新規４―フルオロ安息香酸誘導体 | |
| JPS626703B2 (OSRAM) | ||
| EP0507861A1 (en) | SUBSTITUTED DIAROMATIC ANTI-AIDS COMPOUNDS. | |
| SK2492002A3 (en) | Phenylpiperazine derivatives, process for their preparation and pharmaceutical composition comprising the same | |
| RU2197488C2 (ru) | Производные пиперазина | |
| SK2502003A3 (en) | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine | |
| JPH0460596B2 (OSRAM) | ||
| JP3683911B2 (ja) | α−拮抗活性を有するキナゾリニル−アミノ誘導体 | |
| TWI281397B (en) | An inhibitor of tumor necrosis factor (TNF-alpha) comprising a benzofuran derivative containing pyridazinyl group as ingredients | |
| EP0527081B1 (fr) | Nouvelles pipérazinylalcoyl-3 dihydro-2,3 4H-benzoxazine-1,3 ones-4 substituées, leur préparation et leur application en thérapeutique | |
| PL183526B1 (pl) | N-podstawione pochodne 3-azabicyklo [3.2.0] heptanu oraz sposób ich wytwarzania | |
| JPS62135464A (ja) | フエニルピペラジン誘導体 | |
| CA2306429C (fr) | Derives cyclohexaniques difonctionnalises en 1,4, en tant que ligands des recepteurs 5ht1a | |
| JP4413424B2 (ja) | ５−ｈｔ１ａ受容体のリガンドとしての３−オキソ−２（ｈ）−１，２，４−トリアジン誘導体 | |
| JPH08507302A (ja) | 新規な２−フェノキシエチルアミン誘導体、その調製およびその治療への使用 | |
| JP2815218B2 (ja) | ピリミジンジオン誘導体、およびそれを含有する抗不整脈剤 | |
| PT101158B (pt) | Processo para a preparacao de novos derivados de benzofuranilimidazol | |
| JPH10510253A (ja) | ウラシル誘導体 | |
| WO1994011363A1 (fr) | Derive de 2-alcoxy-5,6,7,8-tetrahydroquinoxaline, son procede de production, et son utilisation | |
| RS20060621A (sr) | Piperazinski derivati alkil oksindola | |
| JPH01117875A (ja) | ２位置に置換基を有するモノアリ−ル−５非均整トリアジノン−３とその製造方法 | |
| MXPA00003772A (en) | 3-oxo-2(h)-1,2,4-triazine derivatives as ligands of 5ht1a receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060905 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070320 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070620 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070806 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070719 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070820 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070912 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080318 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080416 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110425 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120425 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120425 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130425 Year of fee payment: 5 |
|
| LAPS | Cancellation because of no payment of annual fees |